Skip to main content
. 2020 Dec 5;11(12):1035. doi: 10.1038/s41419-020-03241-y

Fig. 5. Chemoresistant MB is susceptible to combination treatment of vincristine with cisplatin or niclosamide.

Fig. 5

Med8A-S, Med8A-R, and Med8A-S-IL6+ cells were treated with vincristine alone or in combination with (a) cisplatin and (b) niclosamide at the indicated concentrations for 48 h and cell viability assessed with CTB. As plotted is the mean ± SD of three replicates; ***p < 0.001, two-way ANOVA with Tukey’s multiple comparison test (Significance not highlighted in the figure is presented in Supplementary Table 1).